Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
Ghione P, Palomba ML, Ray MD, Limbrick-Oldfield EH, Owen J, Kanters S, Bobillo S, Ribiero MT, Jacobson CA, Neelapu SS, Ghesquieres H, Nahas M, Beygi S, Patel AR, Gribben JG. Ghione P, et al. Among authors: gribben jg. Clin Lymphoma Myeloma Leuk. 2024 May;24(5):e191-e195.e6. doi: 10.1016/j.clml.2024.01.011. Epub 2024 Jan 24. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38365528
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Palomba ML, Ghione P, Patel AR, Nahas M, Beygi S, Hatswell AJ, Kanters S, Limbrick-Oldfield EH, Wade SW, Ray MD, Owen J, Neelapu SS, Gribben J, Radford J, Bobillo S. Palomba ML, et al. Expert Rev Anticancer Ther. 2023 Feb;23(2):199-206. doi: 10.1080/14737140.2023.2171994. Epub 2023 Feb 10. Expert Rev Anticancer Ther. 2023. PMID: 36723678 Free PMC article.
MD-1 downregulation is associated with reduced cell surface CD180 expression in CLL.
Edwards K, Manoussaka M, Sayed U, Tsertsvadze T, Deyn L, Nathwani A, Gribben JG, Krysov S, Volpi EV, Lydyard PM, Porakishvili N. Edwards K, et al. Among authors: gribben jg. Leuk Res. 2024 Aug;143:107540. doi: 10.1016/j.leukres.2024.107540. Epub 2024 Jun 11. Leuk Res. 2024. PMID: 38897026 Free article.
Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia.
Borek WE, Nobre L, Pedicona SF, Campbell AE, Christopher JA, Nawaz N, Perkins DN, Moreno-Cardoso P, Kelsall J, Ferguson HR, Patel B, Gallipoli P, Arruda A, Ambinder AJ, Thompson A, Williamson A, Ghiaur G, Minden MD, Gribben JG, Britton DJ, Cutillas PR, Dokal AD. Borek WE, et al. Among authors: gribben jg. EBioMedicine. 2024 Oct;108:105316. doi: 10.1016/j.ebiom.2024.105316. Epub 2024 Sep 17. EBioMedicine. 2024. PMID: 39293215 Free PMC article.
PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.
D'Avola A, Legrave N, Tajan M, Chakravarty P, Shearer RL, King HW, Kluckova K, Cheung EC, Clear AJ, Gunawan AS, Zhang L, James LK, MacRae JI, Gribben JG, Calado DP, Vousden KH, Riches JC. D'Avola A, et al. Among authors: gribben jg. J Clin Invest. 2024 Feb 15;134(4):e179917. doi: 10.1172/JCI179917. J Clin Invest. 2024. PMID: 38357928 Free PMC article. No abstract available.
CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach.
Dreger P, Corradini P, Gribben JG, Glass B, Jerkeman M, Kersten MJ, Morschhauser F, Mussetti A, Viardot A, Zinzani PL, Sureda A; European Society for Blood and Marrow Transplantation and the European Hematology Association Lymphoma Group. Dreger P, et al. Among authors: gribben jg. Lancet Haematol. 2023 Dec;10(12):e1006-e1015. doi: 10.1016/S2352-3026(23)00307-1. Lancet Haematol. 2023. PMID: 38030311 Review.
376 results